JUN 20, 2018 10:30 AM PDT

Panel Discussion: VA Genomics - The Clinic and Research

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Chief Officer of Specialty Care Services, Veteran Health Administration
    Biography
      Dr. Meyer is the Chief Officer of Specialty Care Services and National Director of Genomic Medicine for the Veterans Health Administration. He is a professor of Dermatology and Internal Medicine at the University of Utah Health Sciences Center. He received his Ph.D. in Molecular Genetics from the University of California at Davis. He studied Medicine at the University of Miami, Florida, and has active board certifications in Internal Medicine, Dermatology and Clinical Genetics. Dr. Meyer has responsibility for the Pain service in the VA and he also has overall oversight of VA policy on opioids. He leads the clinical Genomic Medicine Service which is a centralized clinical telehealth service which delivers genetic service to Veterans in over 80 VA hospitals nationwide.
    • Director of Genomic Medicine and Implementation, Department of Veterans Affairs
      Biography
        Ronald M. Przygodzki, M.D. holds a degree in medicine from the Medical University of Warsaw, Poland. He is board certified in anatomic and clinical pathology (American Board of Pathology), with subspecialization in molecular genetic pathology (American Board of Pathology and American Board of Medical Genetics). He has over 25 years of research and clinical experience with over 15 years of administrative experience. He is Director of Genomic in Implementation, and Associate Director of the Genomic Medicine Program. His previous leadership roles (private and public sectors) include being Director, Biomedical Laboratories R&D at the US Department of Veterans Affairs, as Chief of Pathology at the Children's National Medical Center and as Associate Director of the Molecular Diagnostics Laboratory at the Armed Forces Institute of Pathology, all in Washington DC. He conceptualized, drafted and guided implementation of the Million Veterans Program, one of the largest mega-biobank worldwide. Dr. Przygodzki's research expertise and interests are in anatomic and clinical pathology and molecular genomics, spanning from the theoretical to practical clinically translatable arenas. He has developed unique molecular-based techniques-in particular, ones invented around the use of small archival tissue specimens typically found in pathology. He has authored numerous publications, book chapters, and books. Some of his molecular pathology research efforts led to the reclassification of two pulmonary malignancies by the World Health Organization, and have allowed him to receive national and international recognition. His current aims are targeting pharmacogenomic combinatorial analyses to help guide opioid and major depression therapies.

      Abstract:

      With nearly 9 million covered lives serviced through over 150 medical centers, the VA is one of the largest, unified Healthcare System within the United States. Embedded within this system is a large intramural research program spanning biomedical, clinical, rehabilitative and healthcare delivery research program. Just over  10 years ago, the Veterans Healthcare Administration declared a need to invest in genomic medicine both in research and healthcare delivery. Ronald M. Przygodzki, MD, was brought on to build out the genomic medicine program within the Office of Research and Development, ultimately conceptualizing and leading the efforts to develop the Million Veterans Program, the largest genomic research biobank worldwide. He currently is developing the bridge between genomic research and clinic  as Director, Genomic Medicine Implementation. Dr. Laurence J. Meyer, MD, PhD, was brought on as the National Director, Genomic Medicine where he developed a nationwide telehealth genetic counseling program that services the VA Healthcare system nationwide. Currently, he is the Chief Officer, Specialty Care Services where he leads the modernization of VA healthcare. Both Ron and Larry will be presenting strategies, lessons learned and goals withn genomic medicine to provide the best healthcare to our nation's Veterans. 


      Show Resources
      You May Also Like
      MAY 22, 2018 08:00 AM PDT
      C.E. CREDITS
      MAY 22, 2018 08:00 AM PDT
      DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
      MAY 24, 2018 09:30 AM PDT
      C.E. CREDITS
      MAY 24, 2018 09:30 AM PDT
      DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
      MAY 03, 2018 11:00 AM PDT
      MAY 03, 2018 11:00 AM PDT
      DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
      APR 27, 2018 10:00 AM PDT
      C.E. CREDITS
      APR 27, 2018 10:00 AM PDT
      DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
      MAY 02, 2018 08:00 AM PDT
      C.E. CREDITS
      MAY 02, 2018 08:00 AM PDT
      Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
      AUG 15, 2018 08:00 AM PDT
      C.E. CREDITS
      AUG 15, 2018 08:00 AM PDT
      DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
      Loading Comments...
      Show Resources